Ulixacaltamide

Essential tremor

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted by February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

15 evidence topics · 10 sources

Beta-Adrenergic blockers1 evidence topic · 1 source
Antiseizure medications2 evidence topics · 1 source
Benzodiazepines1 evidence topic · 1 source
Botulinum toxin injections1 evidence topic · 1 source
Deep brain stimulation1 evidence topic · 1 source
Ablative thalamic procedures1 evidence topic · 2 sources
Peripheral nerve stimulation1 evidence topic · 1 source
Adaptive equipment and occupational strategies1 evidence topic · 1 source
Limitations of current therapies6 evidence topics · 5 sources